BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
calcium channel activity
,
Influenza
,
Liver
,
Metabolism of nitric oxide
,
Fluoxetine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
EphA2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Pharyngeal mucosa
Esophagus
Oral mucosa
Salivary gland
Conjunctiva
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Cataract
Liver transplant disorder
Hyperoxia
Zika virus disease
Interstitial lung disease
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
propargite
MRK 003
Histidinol
Britanin
pydrin, (S-(R*,R*))-isomer
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
TBC1D23
LCK
EPHA2
GSDME
LAT
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in …
EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colo…
Oncogenic functions and therapeutic targeting of EphA2 in cancer.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ